A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer

Gastric Cancer

Volumn 12, Issue 4, 2009, Pages 212-218

  Yoshikawa, Takaki ^a   Tsuburaya, Akira ^a   Shimada, Ken ^b   Sato, Atsushi ^c   Takahashi, M Akoto ^d   Koizumi, Wasaburo ^e   Yoshizawa, Yasuo ^f   Nabeshima, Kazuhito ^g   Kimura, Masayuki ^h   Hataya, Kiyoshi ⁱ   Kobayashi, Osamu ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY HOSPITAL   (Japan)

^d Kamishirane Hospital   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^g TOKAI UNIVERSITY   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ General of the Hospital   (Japan)

Author keywords

Chemotherapy; Docetaxel; Doxifluridine; Gastric cancer; Phase II

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXIFLURIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ANTINEOPLASTIC AGENT; FLOXURIDINE; TAXOID;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77949895356     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-009-0528-5     Document Type: Article

References (28)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. (Pubitemid 23182046)
3. Glimelius B, Hoffman K, Haglund U Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90. (Pubitemid 24062577)
4. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7. (Pubitemid 30189900)
5. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20. (Pubitemid 28474225)
6. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by 3-h infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity. Ann Oncol 2001;12:1133-7. (Pubitemid 32834495)
7. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:55-7. (Pubitemid 36604665)
8. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer. a Japanese Cooperative Study Group trial (group A). Jpn J Cancer Chemother 1998;25:1915-24.
9. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer. A cooperative study group trial (group B). Jpn J Cancer Chemother 1999;26:487-96.
10. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994;21:1033-8. (Pubitemid 24225031)
11. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61. (Pubitemid 29455579)
12. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 study. J Clin Oncol 2006;24:4991-7. (Pubitemid 46631401)
13. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama H. Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann 1980;71:112-23. (Pubitemid 10100453)
14. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, et al. Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) on patients with malignant cancer. Multi-institutional cooperative study. Jpn J Cancer Chemother 1985;12:2044-51. (Pubitemid 17215003)
15. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81. (Pubitemid 28342121)
16. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1996;4:1013-9. (Pubitemid 28183404)
17. Nishimura R, Tominaga T, Mitsuyama S, Aoyama H, Asaga T, Ohno S, et al. Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval. Anticancer Res 2004;24:2085-91. (Pubitemid 38954638)
18. Sato A, Shimada K, Matsukawa M, Taguchi S. A phase I study of combination chemotherapy of docetaxel and doxifluridine for unresectable or recurrent gastric cancer. Presented at the 76th annual meeting of the Japanese Gastric Cancer Association, 2004. p. 1646.
19. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/ doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008;38:176-81. (Pubitemid 351419740)
20. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). Presented at the 43rd Annual Meeting of American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007 (abstract LBA4513).
21. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 2008;9:215-21.
22. Imamura H, Ishii H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (abstract 5).
23. Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005;25:2973-8. (Pubitemid 41044689)
24. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracilbased regimen. Am J Clin Oncol 2004;27:477-80. (Pubitemid 39371942)
25. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol 2008;63:1-8.
26. Nguyen S, Rebischung C, Van Onqueval J, Flesch M, Bennamoun M, André T, et al. Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer 2006; 93: E1-6.
27. Rosati G, Bilancia D, Germano D, Dinota A, Romano R, Reggiardo G, et al. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. Ann Oncol 2007;18:128-32.
28. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 2007;10:104-11. (Pubitemid 46955936)